What does Agomab Therapeutics NV do?

Agomab Therapeutics NV is a public company in the Biological Products, (No Diagnostic Substances) industry, incorporated in C9. It is registered with the SEC under CIK 0002020932 and trades on NASDAQ under the ticker AGMB.

How many SEC filings has Agomab Therapeutics NV made?

Agomab Therapeutics NV has filed 25 documents with the SEC since 2024. These include annual reports (10-K), quarterly reports (10-Q), current event notices (8-K), and insider transaction disclosures (Form 4).

Agomab Therapeutics NV

AGMB NASDAQ CIK: 0002020932 Biological Products, (No Diagnostic Substances) Inc. in C9

View on SEC.gov →

Overview All Filings Annual Quarterly Insiders

Recent Filings

All 25 filings →

Form	Description	Date
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026
3	OWNERSHIP DOCUMENT	Mar 18, 2026

Insider Transactions

View all →

No insider transactions loaded yet.

About This Profile

This page aggregates all publicly available SEC EDGAR data for Agomab Therapeutics NV. Financial figures are sourced from XBRL-tagged 10-K annual reports. Insider transactions are sourced from Form 4 filings required within two business days of a transaction.

Key Financials

Financial data not yet loaded.

Details

CIK: 0002020932
Ticker: AGMB
Exchange: NASDAQ
Incorporated: C9
First Filing: 2024
Total Filings: 25

Biological Products, (No Diagnostic Substances) rankings →